Paper4507516
Chemotherapy through lysosomes with a DNA-daunorubicin complex.
Trouet A and 2 others. Nat New Biol, 1972. Cited by 274 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Chemotherapy through lysosomes with a DNA-daunorubicin complex. Papers, record 4507516. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4507516
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA | Major topic |
| Daunorubicin | Major topic |
| Lysosomes | Major topic |
| Animals | |
| Cells, Cultured | |
| Drug Combinations | |
| Injections, Intravenous | |
| Leukemia, Experimental | |
| Leukemia, Myeloid | |
| Mice | |
| Mice, Inbred DBA | |
| Mice, Inbred Strains | |
| Pinocytosis | |
| Protein Binding | |
| Sarcoma, Experimental | |
| Staphylococcus |
Source PubMed
Cited by60
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 274 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38,531,786 | pH-Dependent Non-Covalent Release of Chemotherapy from Carriers. | Discov Med | 2024 | https://conductscience.org/library/papers/38531786 | PubMed |
| 36,365,245 | pH-Sensitive Targeting of Tumors with Chemotherapy-Laden Nanoparticles: Progress and Challenges. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36365245 | PubMed |
| 31,382,405 | Sustained Release of Minor-Groove-Binding Antibiotic Netropsin from Calcium-Coated Groove-Rich DNA Particles. | Pharmaceutics | 2019 | https://conductscience.org/library/papers/31382405 | PubMed |
| 31,058,802 | Nanomedicines for the Delivery of Biologics. | Pharmaceutics | 2019 | https://conductscience.org/library/papers/31058802 | PubMed |
| 30,954,222 | Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin. | Biochem Biophys Res Commun | 2019 | https://conductscience.org/library/papers/30954222 | PubMed |
| 30,613,436 | Advances in delivery systems for doxorubicin. | J Nanomed Nanotechnol | 2018 | https://conductscience.org/library/papers/30613436 | PubMed |
| 27,974,700 | Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML). | Oncotarget | 2017 | https://conductscience.org/library/papers/27974700 | PubMed |
| 26,568,330 | Penetration and intracellular uptake of poly(glycerol-adipate) nanoparticles into three-dimensional brain tumour cell culture models. | Exp Biol Med (Maywood) | 2016 | https://conductscience.org/library/papers/26568330 | PubMed |
| 9,587,947 | Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. | Pharm Res | 1998 | https://conductscience.org/library/papers/9587947 | PubMed |
| 8,792,417 | Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. | Pharm Res | 1996 | https://conductscience.org/library/papers/8792417 | PubMed |
| 8,431,358 | Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8431358 | PubMed |
| 7,471,318 | Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/7471318 | PubMed |
| 7,397,945 | Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/7397945 | PubMed |
| 7,261,253 | Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7261253 | PubMed |
| 7,108,944 | Phagosomal membrane lipids of LM fibroblasts. | J Membr Biol | 1982 | https://conductscience.org/library/papers/7108944 | PubMed |
| 7,023,715 | Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7023715 | PubMed |
| 6,952,214 | A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. | Proc Natl Acad Sci U S A | 1982 | https://conductscience.org/library/papers/6952214 | PubMed |
| 6,524,928 | Drug targeting by drug entrapment into ultrafine compartments as carriers. | Appl Biochem Biotechnol | 1984 | https://conductscience.org/library/papers/6524928 | PubMed |
| 6,182,024 | Conjugates of adenine 9-alpha-D-arabinofuranoside monophosphate (ara-AMP) with lactosaminated homologous albumin are not immunogenic in the mouse. | Experientia | 1982 | https://conductscience.org/library/papers/6182024 | PubMed |
| 4,598,351 | Lysosomes in cancer cells. | J Clin Pathol Suppl (R Coll Pathol) | 1974 | https://conductscience.org/library/papers/4598351 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4507516
GET https://conductscience.org/api/papers/v1/4507516/cited_by?page=2